Ekso Bionics to Present at H.C. Wainwright 24th Annual Global Investment Conference
Ekso Bionics, a leader in exoskeleton technology, announced its President and COO, Scott Davis, will present virtually at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ekso Bionics, a leader in exoskeleton technology, announced its President and COO, Scott Davis, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The pre-recorded presentation will be available for on-demand viewing starting at 4:00 AM PT / 7:00 AM ET on September 12, 2022, and can be accessed through the investor section of the Ekso Bionics website. Founded in 2005, Ekso Bionics develops innovative wearable robots to enhance human strength and mobility for both medical and industrial applications.
Details
News Market Reaction – EKSO
The recorded move for EKSO in the trading session of this news was -1.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN RAFAEL, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, President and Chief Operating Officer, will be presenting virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.
The pre-recorded presentation will be available to view on-demand as of 4:00 AM PT / 7:00 AM ET, Monday, September 12, 2022 throughout the entirety of the conference and on the investor section of the Company’s website at www.eksobionics.com.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com or follow @EksoBionics on Twitter.
Investor Contact:
David Carey
212-867-1768
investors@eksobionics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.